Cannabinoid Encyclopedia

Focused research review

Cannabinoids and skin/dermatology: what the research says

What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes?

Updated July 2026 13 research sources Human research included

The short answer

What is the bottom line?

Research has examined Cannabinoids and skin/dermatology. This page brings together 1 human-study source, 10 research reviews, and 2 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Cannabinoids and skin/dermatology.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Cannabinoids and skin/dermatology covers Safety, risk, adverse-event, or formulation-specific concerns; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Cannabinoids and skin/dermatology

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, risk, adverse-event, or formulation-specific concerns

This part of the literature focuses on Safety, risk, adverse-event, or formulation-specific concerns. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

1 source

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

10 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

2 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on Cannabinoids and skin/dermatology is not one kind of study. This source set includes 10 narrative or expert reviews, 1 animal study, 1 cell or laboratory study, and 1 clinical study in people. 3

The recorded populations or models include cells or tissue models (5 sources), people or patients (2 sources), and animal models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, risk, adverse-event, or formulation-specific concerns (13 sources). Closely related outcome names can still describe different measurements. 5

The Cannabinoids and skin/dermatology source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science.

On this page, this source examines CBD and safety, risk, adverse-event, or formulation-specific concerns. 1

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 2

Study type
narrative or expert review
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

animal study

Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model.

On this page, this source examines Endocannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 3

Study type
animal study
Population or model
animal models
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
mechanism-focused research

clinical study in people

Cannabinoids in dermatology: a scoping review.

On this page, this source examines Cannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 4

Study type
clinical study in people
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
human research

narrative or expert review

Cannabinoids and Their Receptors in Skin Diseases.

On this page, this source examines Endocannabinoids and safety, risk, adverse-event, or formulation-specific concerns. 5

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, risk, adverse-event, or formulation-specific concerns
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Cannabinoids and skin/dermatology should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence connects cannabinoids with skin, dermatology, or inflammatory skin outcomes?

Relevant research is collected here. The source set includes human research as well as earlier-stage studies. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. narrative or expert review; evidence still limited PubMed 41008526 DOI 10.3390/biom15091219
  2. 2
    Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. narrative or expert review; evidence still limited PubMed 42076122 DOI 10.3390/pharmaceutics18040469
  3. 3
    Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. animal study; mechanism-focused research PubMed 31350927 DOI 10.1111/exd.14012
  4. 4
    Cannabinoids in dermatology: a scoping review. clinical study in people; human research PubMed 30142706
  5. 5
    Cannabinoids and Their Receptors in Skin Diseases. narrative or expert review; evidence still limited PubMed 38003712 DOI 10.3390/ijms242216523
  6. 6
    Cannabis and the skin. narrative or expert review; evidence still limited PubMed 34785006 DOI 10.1016/j.clindermatol.2021.05.006
  7. 7
    Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. narrative or expert review; evidence still limited PubMed 33851375 DOI 10.1055/a-1420-5780
  8. 8
    Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. narrative or expert review; evidence still limited PubMed 33909195 DOI 10.1007/s11033-021-06366-1
  9. 9
    Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. narrative or expert review; evidence still limited PubMed 36439142 DOI 10.3389/fimmu.2022.1029818
  10. 10
    The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. narrative or expert review; evidence still limited PubMed 19608284 DOI 10.1016/j.tips.2009.05.004
  11. 11
    The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. narrative or expert review; evidence still limited PubMed 30138623 DOI 10.1016/j.bcp.2018.08.022
  12. 12
    The potential role of cannabinoids in dermatology. narrative or expert review; evidence still limited PubMed 31599175 DOI 10.1080/09546634.2019.1675854
See all 13 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. narrative or expert review; evidence still limited / 1 linked research note PubMed 42076122
  2. The potential role of cannabinoids in dermatology. narrative or expert review; evidence still limited / 1 linked research note PubMed 31599175
  3. Cannabis and the skin. narrative or expert review; evidence still limited / 1 linked research note PubMed 34785006
  4. Cannabinoids in dermatology: a scoping review. clinical study in people; human research / 1 linked research note PubMed 30142706
  5. Cannabinoids and Their Receptors in Skin Diseases. narrative or expert review; evidence still limited / 1 linked research note PubMed 38003712
  6. Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. narrative or expert review; evidence still limited / 1 linked research note PubMed 41008526
  7. Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 33851375
  8. Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38904694
  9. Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. narrative or expert review; evidence still limited / 1 linked research note PubMed 33909195
  10. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 30138623
  11. Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. narrative or expert review; evidence still limited / 1 linked research note PubMed 36439142
  12. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. narrative or expert review; evidence still limited / 1 linked research note PubMed 19608284
  13. Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. animal study; mechanism-focused research / 1 linked research note PubMed 31350927